Smithbridge Asset Management Inc. DE Has $12.34 Million Stake in Stryker Corporation $SYK

Smithbridge Asset Management Inc. DE raised its stake in Stryker Corporation (NYSE:SYK) by 99.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 35,120 shares of the medical technology company’s stock after buying an additional 17,488 shares during the quarter. Smithbridge Asset Management Inc. DE’s holdings in Stryker were worth $12,344,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of Stryker by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 33,907,291 shares of the medical technology company’s stock worth $11,917,396,000 after acquiring an additional 133,892 shares during the last quarter. Geode Capital Management LLC boosted its position in Stryker by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 7,535,572 shares of the medical technology company’s stock valued at $2,636,238,000 after purchasing an additional 69,851 shares during the last quarter. Alliancebernstein L.P. increased its position in Stryker by 13.3% in the 3rd quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock worth $2,342,987,000 after purchasing an additional 741,542 shares during the last quarter. Norges Bank purchased a new stake in shares of Stryker during the 4th quarter worth about $1,822,272,000. Finally, Legal & General Group Plc lifted its holdings in shares of Stryker by 2.7% during the 4th quarter. Legal & General Group Plc now owns 2,366,107 shares of the medical technology company’s stock valued at $831,616,000 after buying an additional 62,817 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on SYK shares. Barclays dropped their price objective on Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a report on Monday, May 4th. Canaccord Genuity Group dropped their price target on shares of Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Leerink Partners reduced their price objective on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research note on Friday, June 5th. UBS Group reduced their price objective on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a research note on Tuesday, March 17th. Finally, William Blair restated an “outperform” rating on shares of Stryker in a research note on Thursday, March 5th. Sixteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $395.33.

Stryker Price Performance

NYSE SYK opened at $308.50 on Thursday. The firm’s 50 day moving average is $317.20 and its 200-day moving average is $344.64. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $118.27 billion, a PE ratio of 35.71, a price-to-earnings-growth ratio of 1.98 and a beta of 0.78. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $404.87.

Stryker (NYSE:SYK) last released its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. During the same period last year, the business posted $2.84 EPS. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities research analysts anticipate that Stryker Corporation will post 14.98 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s dividend payout ratio is currently 40.74%.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the transaction, the director owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This trade represents a 13.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP M Kathryn Fink sold 3,500 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $283.45, for a total value of $992,075.00. Following the completion of the sale, the vice president owned 177 shares in the company, valued at $50,170.65. This represents a 95.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 323,264 shares of company stock worth $100,659,489 over the last quarter. 4.60% of the stock is currently owned by insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.